Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference

The new mini-textbook by Kamps & Hoffmann
PDF, 110 pages


  Breast Cancer

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 28 articles:
HTML format
Text format



Single Articles


    March 2020
  1. SPRING LM, Wander SA, Andre F, Moy B, et al
    Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future.
    Lancet. 2020;395:817-827.
    PubMed     Text format     Abstract available


    February 2020
  2. EARL HM, Hiller L, Plummer C, Miles D, et al
    Protective strategies to prevent trastuzumab-induced cardiotoxicity - Authors' reply.
    Lancet. 2020;395:492-493.
    PubMed     Text format    


  3. GUO S, Tse G, Liu T
    Protective strategies to prevent trastuzumab-induced cardiotoxicity.
    Lancet. 2020;395:491-492.
    PubMed     Text format    


  4. LANE R
    Geraldine McGinty: leading light in US radiology.
    Lancet. 2020;395:407.
    PubMed     Text format    


    January 2020
  5. CHUMSRI S, Thompson EA
    Carryover effects of aromatase inhibitors in prevention.
    Lancet. 2020;395:91-92.
    PubMed     Text format    


  6. THE LANCET
    Biosimilars: a new era in access to breast cancer treatment.
    Lancet. 2020;395:2.
    PubMed     Text format    


    December 2019
  7. COLES CE, Bliss JM, Poortmans PM
    Accelerated partial breast irradiation: more questions than answers?
    Lancet. 2019;394:2127-2129.
    PubMed     Text format    


  8. CUZICK J, Sestak I, Forbes JF, Dowsett M, et al
    Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial.
    Lancet. 2019 Dec 11. pii: S0140-6736(19)32955.
    PubMed     Text format     Abstract available


  9. VICINI FA, Cecchini RS, White JR, Arthur DW, et al
    Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial.
    Lancet. 2019 Dec 5. pii: S0140-6736(19)32514.
    PubMed     Text format     Abstract available


  10. WHELAN TJ, Julian JA, Berrang TS, Kim DH, et al
    External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial.
    Lancet. 2019 Dec 5. pii: S0140-6736(19)32515.
    PubMed     Text format     Abstract available


    October 2019
  11. SESSLER DI, Pei L, Huang Y, Fleischmann E, et al
    Recurrence of breast cancer after regional or general anaesthesia: a randomised controlled trial.
    Lancet. 2019 Oct 18. pii: S0140-6736(19)32313.
    PubMed     Text format     Abstract available


  12. ABDALLAH FW, Wijeysundera DN
    Anaesthetic interventions and long-term tumour recurrence.
    Lancet. 2019 Oct 18. pii: S0140-6736(19)32314.
    PubMed     Text format    


    August 2019
  13. KOTSOPOULOS J
    Menopausal hormones: definitive evidence for breast cancer.
    Lancet. 2019 Aug 29. pii: S0140-6736(19)31901.
    PubMed     Text format    



  14. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence.
    Lancet. 2019 Aug 29. pii: S0140-6736(19)31709.
    PubMed     Text format     Abstract available


  15. BERAL V, Peto R, Pirie K, Reeves G, et al
    Menopausal hormone therapy and 20-year breast cancer mortality.
    Lancet. 2019 Aug 29. pii: S0140-6736(19)32033.
    PubMed     Text format    


    June 2019
  16. HURVITZ SA
    Is the duration of adjuvant trastuzumab debate still clinically relevant?
    Lancet. 2019;393:2565-2567.
    PubMed     Text format    


  17. PIVOT X, Romieu G, Debled M, Pierga JY, et al
    6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
    Lancet. 2019 Jun 6. pii: S0140-6736(19)30653.
    PubMed     Text format     Abstract available


  18. EARL HM, Hiller L, Vallier AL, Loi S, et al
    6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
    Lancet. 2019 Jun 6. pii: S0140-6736(19)30650.
    PubMed     Text format     Abstract available


    February 2019
  19. MUTEBI M
    Africa rising: gendered journeys of women patients and providers.
    Lancet. 2019;393:517-518.
    PubMed     Text format    


  20. HURVITZ SA
    Dose intensification of chemotherapy for early breast cancer in the age of de-escalation.
    Lancet. 2019 Feb 7. pii: S0140-6736(19)30197.
    PubMed     Text format    



  21. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.
    Lancet. 2019 Feb 7. pii: S0140-6736(18)33137.
    PubMed     Text format     Abstract available


    December 2018
  22. LEVY A, Chargari C, Deutsch E, Rivera S, et al
    Concerns about cardiotoxicity in the HERA trial.
    Lancet. 2018;390:2767.
    PubMed     Text format    


  23. CAMERON DA, Gelber RD, Procter M, Suter T, et al
    Concerns about cardiotoxicity in the HERA trial - Authors' reply.
    Lancet. 2018;390:2767-2768.
    PubMed     Text format    


    August 2018
  24. WILLER H
    Breast cancer in Venezuela: back to the 20th century.
    Lancet. 2018;392:461-462.
    PubMed     Text format    


    June 2018
  25. SHEIKH S, Sasieni P
    When should the errors in the UK's breast screening programme have been spotted?
    Lancet. 2018;391:2319-2320.
    PubMed     Text format    


    February 2018
  26. MCPHERSON K, Al Waheidi S
    The overestimation and the inappropriate promotion of the benefits of mammographic screening in breast cancer research and interventions in the Gaza Strip.
    Lancet. 2018;391 Suppl 2:S21.
    PubMed     Text format     Abstract available


    January 2018
  27. COLES CE, Haviland JS, Kirby AM, Titley J, et al
    Targeted radiotherapy for early breast cancer - Authors' reply.
    Lancet. 2018;391:27-28.
    PubMed     Text format    


  28. VAIDYA JS, Bulsara M, Wenz F, Tobias JS, et al
    Targeted radiotherapy for early breast cancer.
    Lancet. 2018;391:26-27.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: